

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

**ELECTIONS RELATING TO BOARD OF DIRECTORS, BOARD
COMMITTEES AND BOARD OF SUPERVISORS**

References are made to the announcement of CanSino Biologics Inc. (the “**Company**”) dated January 19, 2024, the circular of the Company dated January 30, 2024 (the “**Circular**”) and the poll results announcement of the Company dated February 21, 2024, in relation to, among others, (i) the election of Directors of the third session of the Board of Directors; and (ii) the election of Supervisors of the third session of the Board of Supervisors. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

The Board of Directors hereby announces that on February 23, 2024, at the first meeting of the third session of the Board of Directors, the Board of Directors has resolved and approved the elections relating to the Board of Directors and Board committees, all with effect from February 23, 2024. On the same date, at the first meeting of the third session of the Board of Supervisors, the Board of Supervisors has resolved and approved the election relating to the Board of Supervisors, with effect from February 23, 2024.

Details of these resolutions are set forth below.

1. Election of the chairman of the Board of Directors

At the first meeting of the third session of the Board of Directors, Dr. Xuefeng YU was elected as the chairman of the third session of the Board of Directors.

2. Elections of members of the Board committees

At the first meeting of the third session of the Board of Directors, the Board of Directors has resolved and approved the elections of the various members to the three Board committees of the third session of the Board of Directors as follow:

Audit Committee

Mr. Yiu Leung Andy CHEUNG (*Chairman*)

Mr. Shuifa GUI

Mr. Jianzhong LIU

Remuneration and Assessment Committee

Mr. Shuifa GUI (*Chairman*)

Mr. Yiu Leung Andy CHEUNG

Dr. Xuefeng YU

Nomination Committee

Mr. Jianzhong LIU (*Chairman*)
Mr. Yiu Leung Andy CHEUNG
Mr. Shuifa GUI
Ms. Nisa Bernice Wing-Yu LEUNG
Dr. Xuefeng YU

Each of the term of office of committee members in their respective Board committees will be effective from February 23, 2024 until the expiry of the term of the third session of the Board of Directors. For the biographical details of such members and other information required to be disclosed under Rule 13.51(2) of the Hong Kong Listing Rules, please refer to the Circular and the announcement of the Company dated January 19, 2024. As at the date of this announcement, there has been no change to such information except that a service contract dated February 23, 2024 has been entered into between the Company and each of above-mentioned Directors. The remuneration of each of above-mentioned Directors shall be in line with the remuneration plan for the Directors of the third session of the Board of Directors as approved by the Shareholders at the EGM, with reference to, among others, the overall performance of the Company, the prevailing economic condition and market practice.

Following the elections of members of the Board committees, the Company has now met the composition requirements of the Audit Committee, the Remuneration and Assessment Committee, and the Nomination Committee as set out in Rules 3.21, 3.25 and 3.27A of the Hong Kong Listing Rules, respectively.

3. Election of an employee representative Supervisor of the third session of the Board of Supervisors

On February 22, 2024, the Company has held an employee's representatives meeting to elect Ms. Yuan ZHOU ("**Ms. ZHOU**") as an employee representative Supervisor of the third session of the Board of Supervisors.

The biographies of Ms. ZHOU are set out below:

Ms. ZHOU, female, born in 1988, Chinese nationality, with no permanent residency outside China, Master of Laws, worked as a legal assistant in Grandall Law Firm (Tianjin) (國浩律師(天津)事務所) from October 2012 to July 2016. From August 2016 to April 2019, she worked as a legal manager in Herong Futures Co., Ltd. (和融期貨有限責任公司). Since May 2019, she has served successively as legal manager, senior legal manager, deputy legal director of the legal department, and senior director of the legal and compliance department and internal audit department of the Company. She is currently serving as a supervisor in certain subsidiaries of the Company, namely CanSino Biology (Shanghai) Co., Ltd., CanSino (Shanghai) Biotechnology Co., Ltd., CanSino (Shanghai) Biological Research and Development Co., Ltd., Kangbo (Tianjin) Pharmaceutical Technology Co., Ltd. and Bomai (Tianjin) Venture Capital Management Co., Ltd.

Ms. ZHOU has entered into a service contract with the Company dated February 23, 2024. Ms. ZHOU will not receive additional remuneration from the Company to act as an employee representative Supervisor.

Saved as disclosed above, as of the date of this announcement, Ms. ZHOU has confirmed that she (i) does not hold any other positions in the Company or its subsidiaries; (ii) does not have any relationship with any directors, supervisors, senior management or substantial or controlling shareholders of the Company; and (iii) has not held any directorship or supervisor positions in any listed companies in the past three years. As of the date of this announcement, Ms. ZHOU does not have any interest in any shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Saved as disclosed above, as of the date of this announcement, there is no other information in respect of Ms. ZHOU that needs to be disclosed pursuant to Rule 13.51(2) of the Hong Kong Listing Rules, and there is no other matter in respect of her appointment that needs to be brought to the attention of the shareholders of the Company.

4. Election of chairman of the Board of Supervisors

At the first meeting of the third session of the Board of Supervisors, Mr. Zhi XIAO was elected as the chairman of the third session of the Board of Supervisors.

For the biographical details of Mr. Zhi XIAO and another non-employee representative Supervisor, Dr. Zhongqi SHAO, and other information required to be disclosed under Rule 13.51(2) of the Hong Kong Listing Rules, please refer to the Circular and the announcement of the Company dated January 19, 2024. As at the date of this announcement, there has been no change to such information except that a service contract dated February 23, 2024 has been entered into between the Company and each of Mr. Zhi XIAO and Dr. Zhongqi SHAO. Mr. Zhi XIAO and Dr. Zhongqi SHAO will not receive remuneration from the Company to act as non-employee representative Supervisors.

Save as disclosed above, there are no other matters concerning the above-mentioned elections relating to the Board of Directors, Board committees and Board of Supervisors which would require disclosure under Rule 13.51(2) of the Hong Kong Listing Rules or matters which ought to be brought to the attention of the Shareholders and the Hong Kong Stock Exchange.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, February 23, 2024

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO and Ms. Jing WANG as executive directors, Ms. Nisa Bernice Wing-Yu LEUNG as a non-executive director, and Mr. Shuifa GUI, Mr. Jianzhong LIU and Mr. Yiu Leung Andy CHEUNG as independent non-executive directors.